Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease
- PMID: 31002123
- DOI: 10.26355/eurrev_201904_17546
Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease
Abstract
Objective: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a heterogeneous inherited disease characterized by renal and extrarenal manifestations with progressive fluid-filled cyst development leading to end-stage renal disease. Our aim was to evaluate the prevalence of obstructive urological disease in ADPKD patients and possible associations with endothelial dysfunction, nutritional, metabolic and inflammatory markers.
Patients and methods: The study included ADPKD patients and control group, who carried out uroflowmetry, an assessment of renal function, metabolic and nutritional parameters and an evaluation of endothelial dysfunction and atherosclerotic markers, such as Renal Resistive Index (RRI), Intima-Media Thickness (IMT) and Flow-Mediated Dilation (FMD).
Results: We enrolled 37 ADPKD patients (20 males with 51.0 ± 14.3 years) and 34 control group (18 males with 60.7 ± 14.4 years). We showed a significant reduction in Max Flow Rate (Qmax) (p ≤ 0.001), age (p = 0.006), FMD (p = 0.023) and Voiding Volume (p = 0.053), in addition to a significant increase in Voiding Time and Diastolic Blood Pressure (p ≤ 0.001, p = 0.049; respectively) in ADPKD patients with respect to control group. Moreover, we found a negative correlation between Qmax and creatinine (r= -0.44, p = 0.007), RRI (r= -0.49, p ≤0.001) and intact Parathyroid Hormone (r = -0.329, p = 0.046), while we found a positive correlation between Qmax and MDRD (r = 0.327, p = 0.048) and between Voiding Time and serum uric acid (r= 0.34, p = 0.039) in ADPKD patients with respect to control group.
Conclusions: In our study, we showed an elevated prevalence of urological functional diseases in ADPKD patients; therefore, we suggest to include uroflowmetry in the assessment of these patients, considering the non-invasiveness, repeatability and low cost of the exam. An early intervention could slow down the progression of renal damage and an early screening of the main cardiovascular risk factors could reduce the high morbidity and mortality in ADPKD patients.
Similar articles
-
α-lipoic acid in patients with autosomal dominant polycystic kidney disease.Nutrition. 2020 Mar;71:110594. doi: 10.1016/j.nut.2019.110594. Epub 2019 Sep 27. Nutrition. 2020. PMID: 31790890 Clinical Trial.
-
Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease.Kidney Blood Press Res. 2017;42(6):1290-1302. doi: 10.1159/000486011. Epub 2017 Dec 15. Kidney Blood Press Res. 2017. PMID: 29262409
-
Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.Medicine (Baltimore). 2016 Jul;95(29):e4175. doi: 10.1097/MD.0000000000004175. Medicine (Baltimore). 2016. PMID: 27442639 Free PMC article.
-
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.Nat Rev Nephrol. 2009 Apr;5(4):221-8. doi: 10.1038/nrneph.2009.13. Nat Rev Nephrol. 2009. PMID: 19322187 Free PMC article. Review.
-
Cardiovascular complications in autosomal dominant polycystic kidney disease.Curr Hypertens Rev. 2013 Feb;9(1):2-11. doi: 10.2174/1573402111309010002. Curr Hypertens Rev. 2013. PMID: 23971638 Review.
Cited by
-
Novel non-cystic features of polycystic kidney disease: having new eyes or seeking new landscapes.Clin Kidney J. 2020 Sep 7;14(3):746-755. doi: 10.1093/ckj/sfaa138. eCollection 2021 Mar. Clin Kidney J. 2020. PMID: 33777359 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical